Partner, Third Rock Ventures
Founder, Gilt Groupe
Co-Founder, Sakti3
President and CEO of the Central Indiana Corporate Partnership
Founder, Gilt Groupe
Founding Director, Massachusetts Technology Transfer Center
Executive Partner, Sofinnova Ventures
CEO and Fund Manager, Renaissance Venture Capital Fund
|
Dendreon, the Seattle-based developer of an immune-boosting treatment for prostate cancer, is holding its annual shareholders meeting at its headquarters in Belltown. Shareholders are being asked to elect two new members to the company’s 12-member board of directors, and give the company (NASDAQ: DNDN) the ability to sell another 100 million shares of stock if it chooses.